Do case-only designs yield consistent results across design and different databases? A case study of hip fractures and benzodiazepines

Pharmacoepidemiology and Drug Safety

Volumn 25, Issue , 2016, Pages 79-87

  Requena, Gema ^a   Logie, John ^b   Martin, Elisa ^c   Boudiaf, Nada ^b   González González, Rocío ^c   Huerta, Consuelo ^c   Alvarez, Arturo ^c   Webb, David ^b   Bate, Andrew ^d   García Rodríguez, Luis A ^e   Reynolds, Robert ^f   Schlienger, Raymond ^g   Gardarsdottir, Helga ^h   de Groot, Mark ^h   Klungel, Olaf H ^h   de Abajo, Fancisco ^a,i   Douglas, Ian J ^j  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b GLAXOSMITHKLINE   (United Kingdom)

^c Veterinary Medicines Department   (Spain)

^d PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^e Spanish Center for Pharmacoepidemiological Research ^*  (Spain)

^f PFIZER INC   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

^h UTRECHT UNIVERSITY   (Netherlands)

ⁱ HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^j LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

more..

Author keywords

Benzodiazepines; Case crossover (CXO); Electronic healthcare records databases (DBs); Hip fractures; Pharmacoepidemiology; Self controlled case series (SCCS)

Indexed keywords

BENZODIAZEPINE DERIVATIVE;

AGE; AGED; ARTICLE; CASE STUDY; CLINICAL PROTOCOL; CONFOUNDING VARIABLE; CONTROLLED STUDY; DATA BASE; DRUG EXPOSURE; FEMALE; FEMUR FRACTURE; HIP FRACTURE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; STUDY DESIGN; TREATMENT DURATION; CASE CONTROL STUDY; FACTUAL DATABASE; HIP FRACTURES; METHODOLOGY; STANDARDS;

BENZODIAZEPINES; CASE-CONTROL STUDIES; DATABASES, FACTUAL; FEMALE; HIP FRACTURES; HUMANS; MALE; RESEARCH DESIGN;

EID: 84933574496     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3822     Document Type: Article

References (31)

1. Smeeth L, Donnan PT, Cook DG. The use of primary care databases: case-control and case-only designs. Fam Pract 2006; 23(5): 597-604.
2. Delaney JA, Suissa S. The case-crossover study design in pharmacoepidemiology. Stat Methods Med Res 2009; 18(1): 53-65.
3. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991; 133(2): 144-153.
4. Hebert C, Delaney JA, Hemmelgarn B, Levesque LE, Suissa S. Benzodiazepines and elderly drivers: a comparison of pharmacoepidemiological study designs. Pharmacoepidemiol Drug Saf 2007; 16(8): 845-849.
5. Farrington CP. Control without separate controls: evaluation of vaccine safety using case-only methods. Vaccine 2004; 22(15-16): 2064-2070.
6. Whitaker HJ, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med 2006; 25(10): 1768-1797.
7. Farrington CP, Whitaker HJ. Semiparametric analysis of case series data. J Roy Stat Soc 2006; 55(5): 553-594.
8. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 1989; 262(23): 3303-3307.
9. Cumming RG, Le Couteur DG. Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs 2003; 17(11): 825-837.
10. Williams T, Van Staa T, Puri S, et al. Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource. Ther Adv Drug Saf 2012; 3(2): 89-99.
11. Abbing-Karahagopian V, Kurz X, deVries F, et al. Bridging differences in outcomes of pharmacoepidemiological studies: design and first results of the protect project. Curr Clin Pharmacol 2014; 9: 130-138.
12. ENCePP ENoCfPaP. ENCePP (European Network of Centres for Pharmacoepidemiology and Pharmacovigilance). Available at: http://www.encepp.eu/encepp/studiesDatabase.jsp [October 2012].
13. Requena G, Huerta C, Gardarsdottir H, et al. Hip/femur fractures associated with the use of BZDs (benzodiazepines anxiolytics, hypnotics and related drugs): a methodological approach to assess consistencies across databases. Pharmacoepidemiol Drug Saf 2015; (Supplement). DOI: 0.1002/pds.3816.
14. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15(6): 993-1000.
15. WHO CCfDSM. Anatomical Therapeutic Chemical (ATC) Classification system, 2013. Available at: http://www.whocc.no/atc_ddd_index/ [September 2014].
16. Terzano MG, Rossi M, Palomba V, Smerieri A, Parrino L. New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf 2003; 26(4): 261-282.
17. Gardarsdottir H, Souverein PC, Egberts TC, Heerdink ER. Construction of drug treatment episodes from drug-dispensing histories is influenced by the gap length. J Clin Epidemiol 2010; 63(4): 422-427.
18. Zint K, Haefeli WE, Glynn RJ, Mogun H, Avorn J, Sturmer T. Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults. Pharmacoepidemiol Drug Saf 2010; 19(12): 1248-1255.
19. Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J. Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture. Am J Psychiatry 2001; 158(6): 892-898.
20. Mittleman MA, Maclure M, Robins JM. Control sampling strategies for case-crossover studies: an assessment of relative efficiency. Am J Epidemiol 1995; 142(1): 91-98.
21. van Staa TP, Dennison EM, Leufkens HG, Cooper C. Epidemiology of fractures in England and Wales. Bone 2001; 29(6): 517-522.
22. Gibson JE, Hubbard RB, Smith CJ, Tata LJ, Britton JR, Fogarty AW. Use of self-controlled analytical techniques to assess the association between use of prescription medications and the risk of motor vehicle crashes. Am J Epidemiol 2009; 169(6): 761-768.
23. Neutel CI, Perry S, Maxwell C. Medication use and risk of falls. Pharmacoepidemiol Drug Saf 2002; 11(2): 97-104.
24. Berry SD, Lee Y, Cai S, Dore DD. Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents. JAMA Intern Med 2013; 173(9): 754-761.
25. File SE. Behavioural pharmacology of benzodiazepines. Prog Neuropsychopharmacol Biol Psychiatry 1984; 8(1): 19-31.
26. Shrank WH, Patrick AR, Brookhart MA. Healthy user and related biases in observational studies of preventive interventions: a primer for physicians. J Gen Intern Med 2011; 26(5): 546-550.
27. Maclure M, Fireman B, Nelson JC, et al. When should case-only designs be used for safety monitoring of medical products? Pharmacoepidemiol Drug Saf 2012; 21(Suppl 1): 50-61.
28. Maclure M. 'Why me?' versus 'why now?'-differences between operational hypotheses in case-control versus case-crossover studies. Pharmacoepidemiol Drug Saf 2007; 16(8): 850-853.
29. Madigan D, Ryan PB, Schuemie M, et al. Evaluating the impact of database heterogeneity on observational study results. Am J Epidemiol 2013; 178(4): 645-651.
30. Douglas IJ, Evans SJ, Hingorani AD, et al. Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs. BMJ 2012; 345: e4388.
31. Ravera S, van Rein N, de Gier JJ, de Jong-van den Berg LT. A comparison of pharmacoepidemiological study designs in medication use and traffic safety research. Eur J Epidemiol 2012; 27(6): 473-481.